Jasper Therapeutics updates corporate presentation as of October 2023; no specific new data disclosed.

Jasper Therapeutics, Inc.

Furnished updated corporate presentation under Regulation FD; presentation dated October 2023.
Presentation cover slide states Briquilimab is investigational and not approved for any indication.
No financial, clinical, or operational metrics from the presentation are included in the filing.
Company disclaims obligation to update the presentation material in the future.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.